Exercise of Warrants and Issue of Equity

Hemogenyx Pharmaceuticals plc (LSE: HEMO) announces that it has received a notice to exercise warrants over 250,000 new ordinary shares in the Company (the "Warrant Shares").

The Warrant Shares are being issued pursuant to the exercise of warrants granted and announced on 8 May 2025. As announced, the exercise price of the warrants ("Exercise Price") is subject to adjustment in certain circumstances, as set out in the warrant instrument, including a reset of the Exercise Price (as defined therein) if the Company completes a share issuance (or other transaction granting rights to subscribe for equity securities) during the Exercise Period (as defined therein) at a price lower than the Exercise Price. As such, the Exercise Price was adjusted to 180p. Subscription monies of £450,000 have been received by the Company in respect of the exercise.

Admission and Total Voting Rights

Application will be made for the Warrant Shares, which will rank pari passu in all respects with the existing Ordinary Shares of the Company, to be admitted to the FCA official list and to trading on the equity shares (transition) category of the Official List maintained by the FCA and to trading on the main market for listed securities of the LSE, which is expected to occur on or around 8.00 a.m. on 9 September 2025 ("Admission").

Upon Admission (and including the 316,667 new ordinary shares being issued as announced on 26 August 2025), the total number of issued shares and the total number of voting rights in the Company will be 5,293,896.

The above figure of 5,293,896 should be used by shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the share capital of the Company under the Financial Conduct Authority's Disclosure Guidance and Transparency Rules.

The Company will keep the market informed of future developments as trials proceed.